MétaCan
Menu
Back to cohort
Record W4317434066 · doi:10.3389/fpsyt.2022.1079006

Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m)

2023· editorial· en· W4317434066 on OpenAlexaff
David Q. Beversdorf, Evdokia Anagnostou, Antonio Y. Hardan, Paul P. Wang, Craig A. Erickson, Thomas Frazier, Jeremy Veenstra‐VanderWeele

Bibliographic record

VenueFrontiers in Psychiatry · 2023
Typeeditorial
Languageen
FieldNeuroscience
TopicAutism Spectrum Disorder Research
Canadian institutionsHolland Bloorview Kids Rehabilitation Hospital
FundersNational Institutes of HealthQuadrant BiosciencesF. Hoffmann-La RocheRocheAutism SpeaksBrain and Behavior Research FoundationBristol-Myers Squibb
KeywordsAutismBiomarkerPhase (matter)Precision medicineAutism spectrum disorderClinical trialPsychiatryMedicinePsychologyMedical physicsInternal medicinePathologyBiology

Abstract

fetched live from OpenAlex

Editorial on the Research Topic Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials -Phase m) Significant progress has been made in understanding the biology of autism spectrum disorder (ASD), providing rational hypotheses for interventions to address the core symptoms.However, clinical trials of these interventions have failed to yield positive results to date.In many of these studies, a subset of participants appear to respond well, but a significant benefit is not found in the overall intent-to-treat group.Due to the etiological heterogeneity of ASD, we anticipate that this will continue to be a challenge in future clinical trials.It will be critical to identify the patients that are most likely to respond to a treatment and to target those subjects in later phase trials.We Frontiers in Psychiatry frontiersin.orgBeversdorf et al. ./fpsyt. .therefore propose the explicit inclusion of "Phase 2m" as part of the pathway of clinical drug development, specifically for the development of a biomarker profile that can be incorporated into later phase 2 and 3 clinical trials.Such a precision medicine approach has the potential to optimize the likelihood of success in future clinical trials to benefit patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: Editorial
Teacher disagreement score0.019
Threshold uncertainty score0.054

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.030
Meta-epidemiology (narrow)0.0050.001
Meta-epidemiology (broad)0.0040.004
Bibliometrics0.0030.001
Science and technology studies0.0030.003
Scholarly communication0.0060.005
Open science0.0040.001
Research integrity0.0190.023
Insufficient payload (model declined to judge)0.0140.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.152
GPT teacher head0.468
Teacher spread0.316 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in PsychiatrySame topicAutism Spectrum Disorder ResearchFrench-language works237,207